Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.
Hyperprogression
Immunotherapy
Lung cancer
Pseudoprogression
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
22
05
2020
accepted:
18
08
2020
pubmed:
29
8
2020
medline:
15
12
2020
entrez:
29
8
2020
Statut:
ppublish
Résumé
Immune checkpoint inhibitors are associated with clinical benefit in lung cancer. However, response patterns to immunotherapy, including pseudoprogression and hyperprogression, are difficult to diagnose, and their mechanisms remain unclear. This review aimed to describe two response patterns observed in lung cancer, namely pseudoprogression and hyperprogression, including their epidemiology, diagnostic characteristics, and plausible mechanisms. We performed a comprehensive literature search in the PubMed database, using keywords "pseudoprogression", "hyperprogression", and "lung cancer", among others. The literature was examined for pseudoprogression and hyperprogression characteristics and plausible mechanisms. Pseudoprogression manifests in multiple forms; however, the immune system-related response criteria and biopsy data are helpful to make accurate diagnosis. Serological biomarkers, such as neutrophil-to-lymphocyte ratio (NLR) and circulating tumor DNA (ctDNA), might help distinguish pseudoprogression from true progression. The incidence of hyperprogression ranges within 5-19.2%, depending on definition. The unique response pattern of rapid progression is observed not only with immunotherapy, but also with other treatment regimens. Molecular mutations and amplifications may result in hyperprogression; however, the exact mechanism remains unclear. Atypical response patterns, such as pseudoprogression and hyperprogression, are increasingly common in clinical practice. Immune-related response criteria can help diagnose pseudoprogression. Molecular mechanisms of hyperprogression remain unclear. Biomarkers for pseudoprogression and hyperprogression are required.
Identifiants
pubmed: 32857178
doi: 10.1007/s00432-020-03360-1
pii: 10.1007/s00432-020-03360-1
doi:
Substances chimiques
Circulating Tumor DNA
0
Immunologic Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3269-3279Subventions
Organisme : National Key Research and Development Program of China
ID : 2018YFC1311400
Organisme : National Natural Science Foundation of China
ID : 81672982
Références
Albert NL, Weller M, Suchorska B et al (2016) Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 18(9):1199–1208. https://doi.org/10.1093/neuonc/now058
doi: 10.1093/neuonc/now058
pubmed: 27106405
pmcid: 4999003
Alexander JL, Gillespie PJ, Edelstyn GA (1976) Serial bone scanning using technetium 99m diphosphonate in patients undergoing cyclical combination chemotherapy for advanced breast cancer. Clin Nucl Med 1:13–17. https://doi.org/10.1097/00003072-197606000-00004
doi: 10.1097/00003072-197606000-00004
Bagley SJ, Kothari S, Aggarwal C et al (2017) Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106:1–7. https://doi.org/10.1016/j.lungcan.2017.01.013
doi: 10.1016/j.lungcan.2017.01.013
pubmed: 28285682
Barrón F, Cardona AF, Corrales L et al (2018) Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation. J Thorac Dis 10:2166–2178. https://doi.org/10.21037/jtd.2018.03.106
doi: 10.21037/jtd.2018.03.106
pubmed: 29850120
pmcid: 5949490
Beer L, Hochmair M, Prosch H (2018) Pitfalls in the radiological response assessment of immunotherapy. Memo 11(2):138–143. https://doi.org/10.1007/s12254-018-0389-x
doi: 10.1007/s12254-018-0389-x
pubmed: 29983829
pmcid: 6006274
Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026. https://doi.org/10.1056/nejmoa1613683
doi: 10.1056/nejmoa1613683
pubmed: 28212060
pmcid: 5635424
Bensch F, van der Veen EL, Lub-de Hooge MN et al (2018) Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med 24(12):1852–1858. https://doi.org/10.1038/s41591-018-0255-8
doi: 10.1038/s41591-018-0255-8
pubmed: 30478423
Berghoff AS, Preusser M (2018) New developments in brain metastases. Ther Adv Neurol Disord 11:1756286418785502. https://doi.org/10.1177/1756286418785502
doi: 10.1177/1756286418785502
pubmed: 30034538
pmcid: 6048670
Bohnsack O, Hoos A, Ludajic K (1070P) 1070P Adaptation of the immune-related response criteria: irRECIST. Ann Oncol 25(Supplement 4):iv361–iv372. https://doi.org/10.1093/annonc/mdu342.23
doi: 10.1093/annonc/mdu342.23
Borcoman E, Kanjanapan Y, Champiat S et al (2019) Novel patterns of response under immunotherapy. Ann Oncol 30(3):385–396. https://doi.org/10.1093/annonc/mdz003
doi: 10.1093/annonc/mdz003
pubmed: 30657859
Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639. https://doi.org/10.1056/NEJMoa1507643
doi: 10.1056/NEJMoa1507643
pubmed: 26412456
pmcid: 5705936
Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135. https://doi.org/10.1056/NEJMoa1504627
doi: 10.1056/NEJMoa1504627
pubmed: 26028407
pmcid: 26028407
Champiat S, Dercle L, Ammari S et al (2017) Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 23(8):1920–1928. https://doi.org/10.1158/1078-0432.ccr-16-1741
doi: 10.1158/1078-0432.ccr-16-1741
pubmed: 27827313
Champiat S, Ferrar R, Massard C et al (2018) Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol 15(12):748–762. https://doi.org/10.1038/s41571-018-0111-2
doi: 10.1038/s41571-018-0111-2
pubmed: 30361681
Chao HS, Chang CP, Chiu CH et al (2009) Bone scan flare phenomenon in nonsmall-cell lung cancer patients treated with gefitinib. Clin Nucl Med 34:346–349. https://doi.org/10.1097/rlu.0b013e3181a344df
doi: 10.1097/rlu.0b013e3181a344df
pubmed: 19487842
Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33:3541–3543. https://doi.org/10.1200/JCO.2015.61.6870
doi: 10.1200/JCO.2015.61.6870
pubmed: 26261262
pmcid: 4622096
Curioni-Fontecedro A, Ickenberg C, Franzen D et al (2018) Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab. Ann Oncol 28:2040–2041. https://doi.org/10.1093/annonc/mdx233
doi: 10.1093/annonc/mdx233
De Cecco CN, Darnell A, Rengo M et al (2012) Dual-energy CT: oncologic applications. AJR Am J Roentgenol 199:S98–S105. https://doi.org/10.2214/AJR.12.9207
doi: 10.2214/AJR.12.9207
pubmed: 23097174
Desar IM, Mulder SF, Stillebroer AB et al (2009) The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol 48:927–931. https://doi.org/10.1080/02841860902974167
doi: 10.1080/02841860902974167
pubmed: 19452305
Di Giacomo AM, Danielli R, Guidoboni M et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58:1297–1306. https://doi.org/10.1007/s00262-008-0642-y
doi: 10.1007/s00262-008-0642-y
pubmed: 19139884
Doherty MK, Jao K, Shepherd FA et al (2015) Central nervous system pseudoprogression in a patient treated with PD-1 checkpoint inhibitor. J Thorac Oncol 10:e100–101. https://doi.org/10.1097/JTO.0000000000000587
doi: 10.1097/JTO.0000000000000587
pubmed: 26398825
Dulos J, Carven GJ, van Boxtel SJ et al (2012) PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 35:169–178. https://doi.org/10.1097/CJI.0b013e318247a4e7
doi: 10.1097/CJI.0b013e318247a4e7
pubmed: 22306905
Ellestad KK, Thangavelu G, Ewen CL et al (2014) PD-1 is not required for natural or peripherally induced regulatory T cells: severe autoimmunity despite normal production of regulatory T cells. Eur J Immunol 44:3560–3572. https://doi.org/10.1002/eji.201444688
doi: 10.1002/eji.201444688
pubmed: 25236923
Erasmus JJ, Gladish GW, Broemeling L et al (2003) Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 21(13):2574–2582. https://doi.org/10.1200/jco.2003.01.144
doi: 10.1200/jco.2003.01.144
pubmed: 12829678
Ferrara R, Mezquita L, Texier M et al (2018) Hyperprogressive Disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 4(11):1543–1552. https://doi.org/10.1001/jamaoncol.2018.3676
doi: 10.1001/jamaoncol.2018.3676
pubmed: 30193240
pmcid: 6248085
Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867. https://doi.org/10.1038/sj.bdj.2016.860
doi: 10.1038/sj.bdj.2016.860
pubmed: 27718784
pmcid: 5564292
Galldiks N, Kocher M, Ceccon G et al (2020) Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. Neuro-oncology 22(1):17–30. https://doi.org/10.1093/neuonc/noz147
doi: 10.1093/neuonc/noz147
pubmed: 31437274
Gandara DR, von Pawel J, Mazieres J et al (2018) Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK study. J Thorac Oncol 13:1906–1918. https://doi.org/10.1016/j.jtho.2018.08.2027
doi: 10.1016/j.jtho.2018.08.2027
pubmed: 30217492
Garassino M, Cho BC, Kim JH et al (2018) Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol 19(4):521–536. https://doi.org/10.1016/s1470-2045(18)30144-x
doi: 10.1016/s1470-2045(18)30144-x
pubmed: 29545095
Guibert N, Mazieres J, Delaunay M et al (2017) Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma. Oncotarget 8(23):38056–38060. https://doi.org/10.18632/oncotarget.16935
doi: 10.18632/oncotarget.16935
pubmed: 28445137
pmcid: 5514971
Guthrie GJ, Charles KA, Roxburgh CS et al (2013) The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Re Oncol Hematol 88:218–230. https://doi.org/10.1016/j.critrevonc.2013.03.010
doi: 10.1016/j.critrevonc.2013.03.010
Hammer M, Bagley S, Aggarwal C et al (2019) Thoracic imaging of non-small cell lung cancer treated with anti-programmed death receptor-1 therapy. Curr Probl Diagn Radiol 48(2):142–147. https://doi.org/10.1067/j.cpradiol.2018.01.005
doi: 10.1067/j.cpradiol.2018.01.005
pubmed: 29573843
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013
doi: 10.1016/j.cell.2011.02.013
pubmed: 21376230
pmcid: 21376230
Hendriks LEL, Henon C, Auclin E et al (2019) Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thorac Oncol 14(7):1244–1254. https://doi.org/10.1016/j.jtho.2019.02.009
doi: 10.1016/j.jtho.2019.02.009
pubmed: 30780002
Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer: a randomised controlled trial. Lancet 387:1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7
doi: 10.1016/S0140-6736(15)01281-7
pubmed: 26712084
Hodi FS, Oble DA, Drappatz J et al (2008) CTLA-4 blockade with ipilimumab induces signifificant clinical benefifit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 5(9):557–561. https://doi.org/10.1038/ncponc1183
doi: 10.1038/ncponc1183
pubmed: 18665147
Hodi FS, Hwu WJ, Kefford R et al (2016) Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab. J Clin Oncol 34:1510–1517. https://doi.org/10.1200/JCO.2015.64.0391
doi: 10.1200/JCO.2015.64.0391
pubmed: 26951310
pmcid: 5070547
Huang B, Pan PY, Li Q et al (2006) Gr-1+CD115+immature myeloid suppressor cells mediate the development of tumorinduced T regulatory cells and T cell anergy in tumor-bearing host. Cancer Res 66:1123–1131. https://doi.org/10.1158/0008-5472.can-05-1299
doi: 10.1158/0008-5472.can-05-1299
pubmed: 16424049
Huang RY, Francois A, McGray AR et al (2017) Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology 6:e1249561. https://doi.org/10.1080/2162402x.2016.1249561
doi: 10.1080/2162402x.2016.1249561
pubmed: 28197366
Iacovelli R, Massari F, Albiges L et al (2015) Evidence and clinical relevance of tumor flare in patients who discontinue tyrosine kinase inhibitors for treatment of metastatic renal cell carcinoma. Eur Urol 68:154–160. https://doi.org/10.1016/j.eururo.2014.10.034
doi: 10.1016/j.eururo.2014.10.034
pubmed: 25466943
Jensen TJ, Goodman AM, Kato S et al (2019) Genome-wide sequencing of cell-free DNA identifies copy-number alterations that can be used for monitoring response to immunotherapy in cancer patients. Mol Cancer Ther 18(2):448–458. https://doi.org/10.1158/1535-7163.mct-18-0535
doi: 10.1158/1535-7163.mct-18-0535
pubmed: 30523049
Kang MH, Go SI, Song HN et al (2014) The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer 111:452–460. https://doi.org/10.1038/bjc.2014.317
doi: 10.1038/bjc.2014.317
pubmed: 24921916
pmcid: 4119986
Kas B, Talbot H, Ferrara R et al (2020) Clarification of definitions of hyperprogressive disease during immunotherapy for non-small cell lung cancer. JAMA Oncol 6(7):1039–1046. https://doi.org/10.1001/jamaoncol.2020.1634
doi: 10.1001/jamaoncol.2020.1634
pubmed: 32525513
Kato R, Hayashi H, Tanizaki J et al (2017a) Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab. ESMO Open 2:e000145. https://doi.org/10.1136/esmoopen-2016-000145
doi: 10.1136/esmoopen-2016-000145
pubmed: 28761729
pmcid: 5519799
Kato S, Goodman A, Walavalkar V et al (2017b) Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res 23:4242–4250. https://doi.org/10.1158/1078-0432.ccr-16-3133
doi: 10.1158/1078-0432.ccr-16-3133
pubmed: 28351930
pmcid: 5647162
Kazandjian D, Keegan P, Suzman DL et al (2017) Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version1.1-defined disease progression in clinical trials. Semin Oncol 44:3–7. https://doi.org/10.1053/j.seminoncol.2017.01.001
doi: 10.1053/j.seminoncol.2017.01.001
pubmed: 28395760
Kim HK, Heo MH, Lee HS et al (2017) Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. Cancer Chemother Pharmacol 80(3):591–598. https://doi.org/10.1007/s00280-017-3396-4
doi: 10.1007/s00280-017-3396-4
pubmed: 28733892
Kim EY, Park I, Kim YS (2019a) Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer. Thorac Cancer 10(4):1016–1018. https://doi.org/10.1111/1759-7714.12994
doi: 10.1111/1759-7714.12994
pubmed: 30734514
pmcid: 6449229
Kim HK, Baek SW, Jeong Y et al (2019b) Pseudoprogression presenting as intestinal perforation in non-small cell lung cancer treated with anti-PD-1: a case report. Mol Clin Oncol 11(2):132–134. https://doi.org/10.3892/mco.2019.1871
doi: 10.3892/mco.2019.1871
pubmed: 31281646
pmcid: 6589934
Kim CG, Kim KH, Pyo K-H et al (2019c) Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol 30(7):1104–1113. https://doi.org/10.1093/annonc/mdz123
doi: 10.1093/annonc/mdz123
pubmed: 30977778
Kim SH, Choi CM, Lee DH et al (2020) Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-020-03293-9
doi: 10.1007/s00432-020-03293-9
pubmed: 33210210
pmcid: 7519913
Krupitskaya Y, Eslamy HK, Nguyen DD et al (2009) Osteoblastic bone flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy. J Thorac Oncol 4(3):429–431. https://doi.org/10.1097/jto.0b013e3181989e12
doi: 10.1097/jto.0b013e3181989e12
pubmed: 19247091
Kuriyama Y, Kim YH, Nagai H et al (2013) Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinase-positive lung cancer. Case Rep Oncol 6:430–433. https://doi.org/10.1159/000354756
doi: 10.1159/000354756
pubmed: 24019783
pmcid: 3764956
Kurra V, Sullivan RJ, Gainor JF et al (2016) Pseudoprogression in cancer immunotherapy: Rates, time course and patient outcomes. J Clin Oncol 34(15_suppl):6580–6580. https://doi.org/10.1200/JCO.2016.34.15_suppl.6580
doi: 10.1200/JCO.2016.34.15_suppl.6580
Lamichhane P, Karyampudi L, Shreeder B et al (2017) IL-10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer. Cancer Res 77:6667–6678. https://doi.org/10.1158/0008-5472.CAN-17-0740
doi: 10.1158/0008-5472.CAN-17-0740
pubmed: 28993412
pmcid: 5712245
Langen KJ, Galldiks N, Hattingen E et al (2017) Advances in neuro-oncology imaging. Nat Rev Neurol 13(5):279–289. https://doi.org/10.1038/nrneurol.2017.44
doi: 10.1038/nrneurol.2017.44
pubmed: 28387340
Lau SCM, Leighl NB (2019) Hyperprogressive disease with immunotherapy: new directions. J Thorac Dis 11:S1877–S1880. https://doi.org/10.21037/jtd.2019.08.88
doi: 10.21037/jtd.2019.08.88
pubmed: 31632773
pmcid: 6783768
Lee JH, Long GV, Menzies AM et al (2018) Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol 4(5):717–721. https://doi.org/10.1001/jamaoncol.2017.5332
doi: 10.1001/jamaoncol.2017.5332
pubmed: 29423503
pmcid: 5885201
Lemieux J, Guimond J, Laberge F et al (2002) The bone scan flare phenomenon in nonsmall-cell lung cancer. Clin Nucl Med 27:486–489. https://doi.org/10.1097/00003072-200207000-00004
doi: 10.1097/00003072-200207000-00004
pubmed: 12072774
Lin X, Lu T, Xie Z et al (2019) Extracranial abscopal effect induced by combining immunotherapy with brain radiotherapy in a patient with lung adenocarcinoma: a case report and literature review. Thorac Cancer 10(5):1272–1275. https://doi.org/10.1111/1759-7714.13048
doi: 10.1111/1759-7714.13048
pubmed: 30929314
pmcid: 6500971
Liu G, Chen T, Li R et al (2018) Well-controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: a case report. Thorac Cancer 9(9):1190–1193. https://doi.org/10.1111/1759-7714.12799
doi: 10.1111/1759-7714.12799
pubmed: 29978949
pmcid: 6119617
Lo Russo G, Moro M, Sommariva M et al (2019) AntibodyFc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade. Clin Cancer Res 25:989–999. https://doi.org/10.1158/1078-0432.CCR-18-1390
doi: 10.1158/1078-0432.CCR-18-1390
pubmed: 30206165
Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22:231–237. https://doi.org/10.1016/j.coi.2010.01.009
doi: 10.1016/j.coi.2010.01.009
pubmed: 20144856
Masaki K, Ryuya E, Hiroyuki K et al (2018) Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: a case series. Thorac Cancer 9:1782–1787. https://doi.org/10.1111/1759-7714.12894
doi: 10.1111/1759-7714.12894
Matos I, Martin-Liberal J, Hierro C et al (2018) Incidence and clinical implications of a new definition of hyperprogression(HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1)trials. J Clin Oncol 36(15 suppl):3032–3032. https://doi.org/10.1200/jco.2018.36.15_suppl.3032
doi: 10.1200/jco.2018.36.15_suppl.3032
Matsuo N, Azuma K, Hattori S et al (2019) Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor. Int J Cancer 144(5):1170–1179. https://doi.org/10.1002/ijc.31923
doi: 10.1002/ijc.31923
pubmed: 30307035
Melian M, Lorente D, Aparici F et al (2018) Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment. Thorac Cancer 9(12):1770–1773. https://doi.org/10.1111/1759-7714.12873
doi: 10.1111/1759-7714.12873
pubmed: 30276979
pmcid: 6275812
Mellema WW, Burgers SA, Smit EF (2015) Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: a case report. Lung Cancer 87:201–203. https://doi.org/10.1016/j.lungcan.2014.11.014
doi: 10.1016/j.lungcan.2014.11.014
pubmed: 25488861
Mezquita L, Auclin E, Ferrara R et al (2018) Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol 4:351–357. https://doi.org/10.1001/jamaoncol.2017.4771
doi: 10.1001/jamaoncol.2017.4771
pubmed: 29327044
pmcid: 5885829
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584–594. https://doi.org/10.4065/83.5.584
doi: 10.4065/83.5.584
pubmed: 18452692
pmcid: 2718421
Nishino M, Guo M, Jackman DM et al (2011) CT tumor volume measurement in advanced non-small-cell lung cancer: performance characteristics of an emerging clinical tool. Acad radiol 18(1):54–62. https://doi.org/10.1016/j.acra.2010.08.021
doi: 10.1016/j.acra.2010.08.021
pubmed: 21036632
Nishino M, Giobbie-Hurder A, Gargano M et al (2013) Developing a common language for tumor response to immunotherapy: immune related response criteria using unidimensional measurements. Clin Cancer Res 19(14):3936–3943. https://doi.org/10.1158/1078-0432.ccr-13-0895
doi: 10.1158/1078-0432.ccr-13-0895
pubmed: 23743568
pmcid: 3740724
Nishino M, Ramaiya NH, Chambers ES et al (2016) Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer 4:84–93. https://doi.org/10.1186/s40425-016-0193-2
doi: 10.1186/s40425-016-0193-2
pubmed: 28018599
pmcid: 5168591
Pop O, Pirvu A, Toffart AC et al (2012) Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib. J Thorac Oncol 7:e1–e2. https://doi.org/10.1097/jto.0b013e318257fc1d
doi: 10.1097/jto.0b013e318257fc1d
pubmed: 22797152
Popat V, Gerber DE (2019) Hyperprogressive disease: a distinct effect of immunotherapy? J Thorac Dis 11:S262–S265. https://doi.org/10.21037/jtd.2019.01.97
doi: 10.21037/jtd.2019.01.97
pubmed: 30997192
pmcid: 6424758
Powles T, Kayani I, Sharpe K et al (2013) A prospective evaluation of VEGF targeted treatment cessation in metastatic clear cell renal cancer. Ann Oncol 24:2098–2103. https://doi.org/10.1093/annonc/mdt130
doi: 10.1093/annonc/mdt130
pubmed: 23579815
Powles T, Duran I, van der Heijden MS et al (2018) Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391(10122):748–757. https://doi.org/10.1016/s0140-6736(17)33297-x
doi: 10.1016/s0140-6736(17)33297-x
pubmed: 29268948
Raez LE, Cassileth PA, Schlesselman JJ, Sridhar K, Padmanabhan S, Fisher EZ, Baldie PA, Podack ER (2004) Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 22(14):2800–2807. https://doi.org/10.1200/JCO.2004.10.197
doi: 10.1200/JCO.2004.10.197
pubmed: 15254047
Ricciuti B, Genova C, Bassanelli M et al (2019) Safety and efficacy of nivolumab in patients with advanced non-small-cell lung cancer treated beyond progression. Clin Lung Cancer 20:178.e2–185.e2. https://doi.org/10.1016/j.cllc.2019.02.001
doi: 10.1016/j.cllc.2019.02.001
Riely GJ, Kris MG, Zhao B et al (2007) Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13:5150–5155. https://doi.org/10.1158/1078-0432.ccr-07-0560
doi: 10.1158/1078-0432.ccr-07-0560
pubmed: 17785570
Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated nonsmall cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265. https://doi.org/10.1016/s0140-6736(16)32517-x
doi: 10.1016/s0140-6736(16)32517-x
pubmed: 27979383
Saada-Bouzid E, Defaucheux C, Karabajakian A et al (2017) Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 28(7):1605–1611. https://doi.org/10.1093/annonc/mdx178
doi: 10.1093/annonc/mdx178
pubmed: 28419181
Saenger YM, Wolchok JD (2008) The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 8:1
pubmed: 18198818
pmcid: 2935787
Sage PT, Francisco LM, Carman CV et al (2013) The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol 14:152–161. https://doi.org/10.1038/ni.2496
doi: 10.1038/ni.2496
pubmed: 23242415
Sanmamed MF, Perez-Gracia JL, Schalper KA et al (2017) Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients. Ann Oncol 28(8):1988–1995. https://doi.org/10.1093/annonc/mdx190
doi: 10.1093/annonc/mdx190
pubmed: 28595336
pmcid: 5834104
Sarfaty M, Moore A, Dudnik E et al (2017) Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: a case report. Medicine (Baltimore) 96:e5951. https://doi.org/10.1097/MD.0000000000005951
doi: 10.1097/MD.0000000000005951
Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143–e152. https://doi.org/10.1016/s1470-2045(17)30074-8
doi: 10.1016/s1470-2045(17)30074-8
pubmed: 28271869
pmcid: 5648544
Shepherd FA, Papadimitrakopoulou V, Mok T et al (2018) Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial. J Clin Oncol 36:abstr 9027. https://doi.org/10.1200/jco.2018.36.15_suppl.9027
doi: 10.1200/jco.2018.36.15_suppl.9027
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics. CA Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442
doi: 10.3322/caac.21442
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590
doi: 10.3322/caac.21590
pubmed: 31912902
pmcid: 31912902
Singavi AK, Menon S, Kilari D et al (1140PD) Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI)—analysis of somatic alterations (SAs). Ann Oncol 28:1140PD. https://doi.org/10.1093/annonc/mdx376.006
doi: 10.1093/annonc/mdx376.006
Skoulidis F, Goldberg ME, Greenawalt DM et al (2018) STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov 8:822–835. https://doi.org/10.1158/2159-8290.CD-18-0099
doi: 10.1158/2159-8290.CD-18-0099
pubmed: 29773717
pmcid: 6030433
Skoulidis F, Arbour KC, Hellmann MD et al (2019) Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. J Clin Oncol 37:abstr 102. https://doi.org/10.1200/jco.2019.37.15_suppl.102
doi: 10.1200/jco.2019.37.15_suppl.102
Solinas C, Porcu M, Hlavata Z et al (2017) Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. Crit Rev Oncol Hematol 120:13–21. https://doi.org/10.1016/j.critrevonc.2017.09.017
doi: 10.1016/j.critrevonc.2017.09.017
pubmed: 29198327
Song P, Zhang J, Shang C et al (2019) Curative effect assessment of immunotherapy for non-small cell lung cancer: the “blind area” of immune response evaluation criteria in solid tumors (iRECIST). Thoracic Cancer 10(4):587–592. https://doi.org/10.1111/1759-7714.13010
doi: 10.1111/1759-7714.13010
pubmed: 30779329
pmcid: 6449267
Taniguchi Y, Tamiya A, Isa S et al (2017) Predictive factors for poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab. Anticancer Res 37(10):5857–5862. https://doi.org/10.21873/anticanres.12030
doi: 10.21873/anticanres.12030
pubmed: 28982912
Tanizaki J, Hayashi H, Kimura M et al (2016) Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression. Lung Cancer 102:44–48. https://doi.org/10.1016/j.lungcan.2016.10.014
doi: 10.1016/j.lungcan.2016.10.014
pubmed: 27987588
Tazdait M, Mezquita L, Lahmar J et al (2018) Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer 88:38–47. https://doi.org/10.1016/j.ejca.2017.10.017
doi: 10.1016/j.ejca.2017.10.017
pubmed: 29182990
Templeton AJ, McNamara MG, Šeruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106:dju124. https://doi.org/10.1093/jnci/dju124
doi: 10.1093/jnci/dju124
pubmed: 24875653
pmcid: 24875653
Vrankar M, Unk M (2018) Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy. Radiol Oncol 52(4):365–369. https://doi.org/10.2478/raon-2018-0037
doi: 10.2478/raon-2018-0037
pubmed: 30367809
pmcid: 6287173
Wang Q, Gao J, Wu X et al (2018) Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol 58:125–135. https://doi.org/10.1016/j.intimp.2018.03.018
doi: 10.1016/j.intimp.2018.03.018
pubmed: 29579717
Weiss GJ, Beck J, Braun DP et al (2017) Tumor cell-free DNA copy number instability predicts therapeutic response to immunotherapy. Clin Cancer Res 23(17):5074–5081. https://doi.org/10.1158/1078-0432.ccr-17-0231
doi: 10.1158/1078-0432.ccr-17-0231
pubmed: 28320758
Wolchok JD, Hoos A, O’Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immunerelated response criteria. Clin Cancer Res 15:7412–7420. https://doi.org/10.1158/1078-0432.CCR-09-1624
doi: 10.1158/1078-0432.CCR-09-1624
pubmed: 19934295
Wolter P, Beuselinck B, Pans S et al (2009) Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Acta Oncol 48:621–624. https://doi.org/10.1080/02841860802609574
doi: 10.1080/02841860802609574
pubmed: 19107622
Xiong D, Wang Y, Singavi AK et al (2018) Immunogenomic landscape contributes to hyperprogressive disease after Anti-PD-1 immunotherapy for cancer. iScience 9:258–277. https://doi.org/10.1016/j.isci.2018.10.021
doi: 10.1016/j.isci.2018.10.021
pubmed: 30439581
pmcid: 6234258
Yang JJ, Chen HJ, Yan HH et al (2013) Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer 79:33–39. https://doi.org/10.1016/s0923-7534(20)33797-2
doi: 10.1016/s0923-7534(20)33797-2
pubmed: 23079155
Yang K, Blanco DB, Neale G et al (2017) Homeostatic control of metabolic and functional fitness of Treg cells by LKB1 signalling. Nature 548:602–606. https://doi.org/10.1038/nature23665
doi: 10.1038/nature23665
pubmed: 28847007
pmcid: 5804356
Zer A, Sung MR, Walia P et al (2018) Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 19(5):426–434.e1. https://doi.org/10.1016/j.cllc.2018.04.008
doi: 10.1016/j.cllc.2018.04.008
pubmed: 29803574
Zhao B, James LP, Moskowitz CS et al (2009) Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology 252(1):263–272. https://doi.org/10.1148/radiol.2522081593
doi: 10.1148/radiol.2522081593
pubmed: 19561260
pmcid: 2797680
Zhou C, Imamura F, Cheng Y et al (2019) Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial. J Clin Oncol 37:abstr 9020. https://doi.org/10.1200/jco.2019.37.15_suppl.9020
doi: 10.1200/jco.2019.37.15_suppl.9020